381 related articles for article (PubMed ID: 17299132)
1. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M
Genes Dev; 2007 Feb; 21(4):379-84. PubMed ID: 17299132
[TBL] [Abstract][Full Text] [Related]
2. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Shai A; Dankort D; Juan J; Green S; McMahon M
Cancer Res; 2015 Aug; 75(15):3167-80. PubMed ID: 26001956
[TBL] [Abstract][Full Text] [Related]
3. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
4. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
5. p53 loss does not permit escape from Braf
Garnett S; Dutchak KL; McDonough RV; Dankort D
Oncogene; 2017 Nov; 36(45):6325-6335. PubMed ID: 28745322
[TBL] [Abstract][Full Text] [Related]
6. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.
Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG
Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810
[TBL] [Abstract][Full Text] [Related]
7. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
8. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
10. BRAFE600-associated senescence-like cell cycle arrest of human naevi.
Michaloglou C; Vredeveld LC; Soengas MS; Denoyelle C; Kuilman T; van der Horst CM; Majoor DM; Shay JW; Mooi WJ; Peeper DS
Nature; 2005 Aug; 436(7051):720-4. PubMed ID: 16079850
[TBL] [Abstract][Full Text] [Related]
11. Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF
van Veen JE; Scherzer M; Boshuizen J; Chu M; Liu A; Landman A; Green S; Trejo C; McMahon M
Elife; 2019 Aug; 8():. PubMed ID: 31452510
[TBL] [Abstract][Full Text] [Related]
12. A Braf kinase-inactive mutant induces lung adenocarcinoma.
Nieto P; Ambrogio C; Esteban-Burgos L; Gómez-López G; Blasco MT; Yao Z; Marais R; Rosen N; Chiarle R; Pisano DG; Barbacid M; Santamaría D
Nature; 2017 Aug; 548(7666):239-243. PubMed ID: 28783725
[TBL] [Abstract][Full Text] [Related]
13. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.
Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M
Genes Dev; 2014 Mar; 28(6):561-75. PubMed ID: 24589553
[TBL] [Abstract][Full Text] [Related]
14. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
[TBL] [Abstract][Full Text] [Related]
17. Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.
González-Sánchez E; Martín-Caballero J; Flores JM; Hernández-Losa J; ; Cortés J; Mares R; Barbacid M; Recio JA
PLoS One; 2013; 8(6):e66933. PubMed ID: 23825589
[TBL] [Abstract][Full Text] [Related]
18. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
19. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
Rotolo S; Diotti R; Gordon RE; Qiao RF; Yao Z; Phelps RG; Dong J
Int J Cancer; 2005 May; 115(1):164-9. PubMed ID: 15657897
[TBL] [Abstract][Full Text] [Related]
20. Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.
Luo C; Sheng J; Hu MG; Haluska FG; Cui R; Xu Z; Tsichlis PN; Hu GF; Hinds PW
Cancer Res; 2013 Jul; 73(14):4337-48. PubMed ID: 23650282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]